CSL Launches New Flu Vaccine Aujemflu First in the UK Under Extended Agreement

CSL has extended its multi-year Advance Purchase Agreement with the UK government for its Aujemflu vaccine, making the UK the first country to commercially launch this adjuvanted, trivalent cell-based influenza vaccine. The agreement underscores the importance of CSL's UK manufacturing hub in pandemic preparedness and large-scale flu vaccine supply. This launch and purchase extension represent a significant step in CSL's vaccine distribution strategy.

Originally published by gnews